Jubilant Radiopharma and Evergreen Theragnostics Announce Collaboration for the Sale and Distribution of Neuroendocrine Tumor Diagnostic OCTEVY™, Pending FDA Approval in 2H 2023

Jubilant Radiopharma and Evergreen Theragnostics have announced a collaboration for the sale and distribution of Neuroendocrine Tumor Diagnostic OCTEVY, pending FDA approval in 2H 2023. Jubilant will prepare, sell, and distribute doses of OCTEVY to PET customers across the US upon regulatory approval. OCTEVY is currently under evaluation by the FDA as a potential radioactive diagnostic agent ind..